Jasmin Nessler’s Post

"Longest weight-loss medication study conducted to date"... It's exciting to see the results of this study and the impact these medications can have when they are properly placed into a member's treatment plan. Wondr Health takes a highly conservative, thoughtful approach into prescribing these medications. Always matching members to the right medication and continually supporting them with best-in-class behavior change methodologies and superior clinical oversight. #Weightmanagement #GLP1s #obesitymanagement #behaviorchange #medicationmanagement

https://lnkd.in/eQiGtt7W So yet more evidence piling up for the potential of metformin as a therapeutic for Dry AMD, GA, and even new onset Wet AMD. For those of you curious about just how metformin can help, i recommend this easy to understand yet comprehensive article (and this world class researcher).. "It is our best chance to stop a very complex disease." Dimitra Skondra, MD, PhD

Safety, Efficacy and Clinical Applications of Focused Ultrasound-Mediated Blood Brain Barrier Opening in Alzheimer’s Disease: A Systematic Review. Patwardhan, A. et al.. https://lnkd.in/eJKbJC_x

📑A systematic review investigating the positive effects of #physicalactivity on #qualityoflife in #Parkinson’s disease https://brnw.ch/21wMmE4 #QoL #NeurodegenerativeDiseases #exercise2870930 MDPI

Case for shorter and perhaps outpatient treatment of Cell therapy: The ASCO Post recently reported on a study suggesting that the FDA-mandated monitoring period for CAR T-cell therapy could be shortened to 2 weeks instead of 4 wks. 💥 Data included 475 patients from 9 centers infused with axicel, tisacel, and lisocel from 2018 to 2023, aims to assess CRS and ICANS onset and duration, as well as causes of non-relapse mortality (NRM) in real-world CAR T recipients. 💥 The study found that the two main toxicities, cytokine-release syndrome and immune effector cell-associated neurotoxicity syndrome, are rare after two weeks. 💥 It is significant if guidelines were to change this could improve access to treatment for patients with diffuse large B-cell lymphoma (DLBCL). Currently, patients must stay within a two-hour distance of their treatment center for 4 weeks and refrain from driving for eight weeks post-treatment. This adjustment could make it easier for patients, especially those who live far from treatment centers, to receive this potentially life-saving therapy. #Celltherapy #Patientaccess #outpatient #monitoring #Lymphoma #axicel, #tisacel, #lisocel #Kitepharma #Gilead #Novartis #BristolMyersSquibb

Some new studies we published this month. It has been a journey. 1. Immune landscape of the enteric nervous system differentiates Parkinson's disease patients from controls: The PADUA-CESNE cohort (https://lnkd.in/dy-92q56) 2. Carotid body plastic behavior: evidence for D2–H3 receptor–receptor interactions (https://lnkd.in/dYbxDUFF)

Great read on Beta-Blockers The data on beta-blockers are decades old. In the time before stents, statins, angiotensin-converting enzyme inhibitors, and dual antiplatelet therapy, when patients either died or got better on their own, beta-blockers showed major benefits. Studies like the Norwegian Multicenter Study Group, the BHAT trial, and the ISIS-1 trial proved the benefits of beta blockade. These studies date back to the 1980s, when you could call a study ISIS without controversy. It was a simpler time, when all you had to worry about was the Cold War, apartheid, and the global AIDS pandemic. It was a time when doctors smoked in their offices, and patients had bigger infarcts that caused large scars and systolic dysfunction. That world is no longer our world, except for the war, the global pandemic, and the out-of-control gas prices.

📰 Extra, extra, read all about it! #KPMPNews article dropped today! Thrilled to share that KPMP is featured in the latest National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director's Update, highlighting our patient-centered work in kidney disease research. Authored by Steven Winter, the update emphasizes patient engagement in advancing precision medicine. Key highlight: KPMP's creation of the most comprehensive "human kidney cell atlas" to date, enabling personalized treatments. Participants, like Emanuel Holley, and patient partners, such as Christy Stutzke, play a vital role in driving KPMP research forward. Read the full update to learn how we're revolutionizing kidney precision medicine. #KidneyPrecisionMedicineProject #PatientEngagement #NIDDK 🔗 https://lnkd.in/gbuYKAfx

Associate Professor Andrei Maiseyeu and his team have identified an inflammation-reducing molecule that may be the basis of a new approach to treat atherosclerosis. https://bit.ly/3P4f4vo

At BridgeBio, we stand by putting patients first. We recently shared a poster at the Muscular Dystrophy Association Conference 2024 on developing disease-specific patient-reported outcomes (PROs) that assess the impact of LGMD2I/R9 on daily life. Our aim is to develop these to better assess and understand the impact of impaired physical function in individuals with this progressive condition. Learn more about our findings: https://bit.ly/3wEXBnn